Skip to main content
Equibles
MTNB logo

MTNB · Matinas BioPharma Holdings, Inc. · Webcasts, Transcripts & Audio

Track MTNB — free

Use MTNB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MTNB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.82 +0.18 (+6.82%) At close · Oct 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company does not believe that the cash and cash equivalents on hand are sufficient to fund planned operations for a period of at least twelve months from the filing date of these financial statements. As a result, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.48M
Shares
979,520
Volume · Oct 5 183.98K Avg daily vol (5 sessions) 275.08K

Matinas BioPharma Holdings, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Matinas BioPharma Holdings, Inc. (MTNB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $95,833 −$5.45M '20 Q3 20-11-06 · $33,333 −$4.96M '21 Q1 21-05-10 · $1.06M −$5.92M '22 Q2 22-08-11 · $1.06M −$5.46M '22 Q3 22-11-02 LATEST · $1.10M −$5.51M '23 Q1 23-05-10
Earnings call
FY24 · Q2
2024-08-14
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript
Positive tone MAT2203 Licensing Partnership Compassionate/Expanded Use Access Program LNC Platform and Oncology
Diluted EPS
$-17.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
Positive tone MAT2203 partnership and Phase III ORALTO trial LNC platform in oncology Small oligonucleotide delivery (inflammation)
Diluted EPS
$-20.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Confident tone MAT2203 ORALTO Phase III trial design and FDA agreement LNC platform expansion into oncology and inflammation Partnership discussions for MAT2203 commercialization
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
Diluted EPS
$-20.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2023 Earnings Call Transcript
Diluted EPS
$-22.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2023 Earnings Call Transcript
Revenue
$1.10M
Diluted EPS
$-22.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call Transcript
Revenue
$1.06M
Diluted EPS
$-22.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2022 Earnings Call Transcript
Revenue
$1.06M
Diluted EPS
$-22.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2021 Earnings Call Transcript
Revenue
$33,333
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-29
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2020 Earnings Call Transcript
Revenue
$95,833
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-09
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–19 of 19 webcasts
Key facts CIK 1582554 CUSIP 576810303 13F (30d) 1 filings 1 filers Visit website Investor relations